Biomarker Research · Published 2026-04-10 · DOI 10.1186/s40364-026-00912-4
Abstract Bispecific antibodies (BsAbs), which simultaneously target two antigens and redirect immune T cells toward tumor cells, have emerged as one of the most promising immunotherapeutic strategies for multiple myeloma (MM). Based on previously reported clinical data, several BsAbs have been approved for MM patients who relapsed in late-line treatment. At the 2025 ASH Annual Meeting, pivotal trials presented updated findings on BsAbs targeting B-cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor-homolog 5 (FcRH5), evaluated as monotherapies or in combination regimens across patient populations, both at initial diagnosis and at relapse. Here, we summarize the remarkable outcomes from the key clinical trials.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →